Wells Fargo’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-6,800
Closed -$3.08M 7473
2025
Q4
$3.08M Buy
+6,800
New +$2.93M ﹤0.01% 3090
2024
Q4
Sell
-19,000
Closed -$8.84M 7206
2024
Q3
$8.84M Buy
+19,000
New +$9.13M ﹤0.01% 1932
2024
Q2
Sell
-900
Closed -$376K 7507
2024
Q1
$376K Sell
900
-500
-36% -$211K ﹤0.01% 4070
2023
Q4
$570K Hold
1,400
﹤0.01% 3775
2023
Q3
$487K Hold
1,400
﹤0.01% 3800
2023
Q2
$493K Buy
+1,400
New +$472K ﹤0.01% 3951
2021
Q3
Sell
-100,000
Closed -$20.2M 7585
2021
Q2
$20.2M Buy
+100,000
New +$20.9M ﹤0.01% 1676
2016
Q1
Sell
-22,000
Closed -$17K 6456
2015
Q4
$17K Hold
22,000
﹤0.01% 5623
2015
Q3
$285K Sell
22,000
-116,100
-84% -$14.9M ﹤0.01% 4271
2015
Q2
$1.1M Buy
138,100
+2,000
+1% +$252K ﹤0.01% 3521
2015
Q1
$522K Buy
+136,100
New +$16.3M ﹤0.01% 3918

Other funds holding VRTX

Wells Fargo's VRTX Position: Q2 2026 in Review

Wells Fargo increased its Vertex Pharmaceuticals (VRTX) stake by 0.61% in Q2 2026, buying an estimated $2.01M and bringing the position to 749,528 shares worth $372M. The position accounts for 0.06% of the portfolio, ranked #269.

Wells Fargo first reported a position in VRTX in Q2 2013 and has held it in 53 quarters since. The position peaked at $443M in Q2 2020. 1,756 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Wells Fargo held 749,528 shares of Vertex Pharmaceuticals worth $372M as of Q2 2026.
  • Wells Fargo bought 4,533 Vertex Pharmaceuticals shares in Q2 2026, an estimated $2.01M.
  • Vertex Pharmaceuticals made up 0.06% of Wells Fargo's portfolio in Q2 2026, its #269 holding.
  • Wells Fargo first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Wells Fargo's Vertex Pharmaceuticals position peaked at $443M in Q2 2020.
  • 1,756 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.